Replies to post #10874 on AEterna Zentaris Inc. (AEZS)

[$avvyPenny$tockInvestor™]

Repost this and make this the top sticky. We are in for a huge ride. $$$$$$$$$$$$$

$AEZS

[chmcnfunds]

STICKY FACT CHECK. Sticky has many erroneous statements. A few from the prior sticky have been corrected but these remain. Here are bolded checks that are the most glaring. If you agree, feel free to re-post this information. Time to have this sticky updated.

Btw final phase 3 results for ZopTec in endometrial cancer wi be released by the end of 2016.

Expected to be completed by the end of 2016. Results likely later and AEZS known for being late in announcing results.

Option 2. DSMB advices for immediate FDA approval based on superior safety and efficacy

Extremely unlikely possibility. More details regarding this option:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117356232

Price estimates:
Option 1. $.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes

300 million market cap WRONG. Misunderstanding of the Feuerstein-Reitan Rule. Has nothing to do with determining price estimates. Rather it establishes the minimal market cap for a company to to be successful. So AEZS, with a current market cap of approximately $16M-$18M, based on ihub detailed quote, Finviz and Google Finance, according to this “rule” has little chance for success. More on the F-R Rule:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116949306

Option 2. at least $3.5/share or a market cap of 2.5 billion dollar

Not worth addressing as is only hype

Option 3. $.10 based on their latest cash position of $45m and Saizen+Estrogel

Been discussed Ad nauseam that $45M was June 30th and it is now October 6th. With AEZS stated cash burn rate “Cash” probably ~$36M. One of many attempts to correct this incorrect statement:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116948870

The company has sufficient cash until February2017

While true they have cash until February, 2017 it is hardly “sufficient”. They will be down to 0 cash which would severely restrict them. Historically AEZS does an offering whenever cash gets down to about $35M.

Finally, left unsaid is the fact they are facing Nasdaq delisting and are expected to respond to this by mid November by doing a reverse split. Expect an offering after that.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117417542

(I have no shares)

AEZS

[chmcnfunds]

STICKY FACT CHECK. Sticky has many erroneous statements. A few from the prior sticky have been corrected but these remain. Here are bolded checks that are the most glaring. If you agree, feel free to re-post this information. Time to have this sticky updated.

Btw final phase 3 results for ZopTec in endometrial cancer wi be released by the end of 2016.

Expected to be completed by the end of 2016. Results likely later and AEZS known for being late in announcing results.

Option 2. DSMB advices for immediate FDA approval based on superior safety and efficacy

Extremely unlikely possibility. More details regarding this option:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117356232

Price estimates:
Option 1. $.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes

300 million market cap WRONG. Misunderstanding of the Feuerstein-Reitan Rule. Has nothing to do with determining price estimates. Rather it establishes the minimal market cap for a company to to be successful. So AEZS, with a current market cap of approximately $16M-$18M, based on ihub detailed quote, Finviz and Google Finance, according to this “rule” has little chance for success. More on the F-R Rule:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116949306

DSMB-safety/efficacy evaluation-early October

2nd Interim Results: Expected October 2015

Option 2. at least $3.5/share or a market cap of 2.5 billion dollar

Not worth addressing as is only hype

Option 3. $.10 based on their latest cash position of $45m and Saizen+Estrogel

Been discussed Ad nauseam that $45M was June 30th and it is now October 7th. With AEZS stated cash burn rate “Cash” probably ~$36M. One of many attempts to correct this incorrect statement:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116948870

The company has sufficient cash until February2017

While true they have cash until February, 2017 it is hardly “sufficient”. They will be down to 0 cash which would severely restrict them. Historically AEZS does an offering whenever cash gets down to about $35M.

Finally, left unsaid is the fact they are facing Nasdaq delisting and are expected to respond to this by mid November by doing a reverse split. Expect an offering after that.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117417542

(I have no shares)

AEZS